Mydecine Innovations Group Inc.

Mydecine Innovations Group™ (CSE:MYCO) is a publicly traded life sciences syndicate, with offices in Denver, CO, USA and Vancouver, BC, Canada.

Mydecine is dedicated to the development and production of adaptive pathway medicine and natural health products all stemming from mushrooms. Mydecine’s experienced multi-talented team has the dynamic capabilities to oversee all areas of Schedule I drug development, including but not limited to synthesis, genetic research, delivery mechanism design, clinical trial execution; through to worldwide product commercialization, marketing and spore-to-sale™ distribution of cGMP psilocybin API’s and non-psychedelic medicinal fungi.

By leveraging strategic partnerships with global scientific, medical, clinical, and Veteran organizations; Mydecine is well positioned at the forefront of naturally derived medicine, alternative therapeutics, and fungtional™ mushroom vitality consumer goods. Our portfolio of unified companies, including Mydecine Health Sciences™, Mindleap Health™, and NeuroPharm™ focus together on providing innovative and effective solutions that can help millions of people live a healthier quality life.

View in the Microdose DirectoryVisit Website